{"id":11521,"date":"2020-12-29T13:36:52","date_gmt":"2020-12-29T08:06:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11521"},"modified":"2021-07-24T12:58:12","modified_gmt":"2021-07-24T07:28:12","slug":"pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","title":{"rendered":"A USD 4.2 Billion Myovant\/ Pfizer Deal; Audentes Therapeutics\u2019 ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f13b1be3a07\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f13b1be3a07\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\/#A_USD_42_Billion_Myovant_Pfizer_Deal\" >A USD 4.2 Billion Myovant\/ Pfizer Deal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\/#Audentes_Therapeutics_ASPIRO_Trial_Free_to_Proceed\" >Audentes Therapeutics\u2019 ASPIRO Trial Free to Proceed&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\/#Welcome_the_First_Generic_of_Drug_for_Severe_Hypoglycemia\" >Welcome the First Generic of Drug for Severe Hypoglycemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\/#Teleflex_Acquires_Z-Medica\" >Teleflex Acquires Z-Medica<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_USD_42_Billion_Myovant_Pfizer_Deal\"><\/span><strong>A USD 4.2 Billion Myovant\/ Pfizer Deal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Myovant Sciences have decided to put their forces and efforts together to advance the <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market?utm_source=blog&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Prostate cancer market<\/a> as they announced their partnership deal to develop and market relugolix for prostate cancer and women\u2019s health.\u00a0<\/p>\n\n\n\n<p>Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. If approved, it will be marketed under the brand name Orgovyx for <a href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-market\/?utm_source=blog&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">prostate cancer<\/a> as well as in women\u2019s health in combination with estradiol 1.0 mg and norethindrone acetate (0.5 mg) in the US and Canada. However, for geographies other than the US and Canada, Pfizer has received an exclusive right to develop the drug in oncology except in certain Asian countries.<\/p>\n\n\n\n<p>While Myovant is planning to handle regulatory interactions, drug supply, and advance the relugolix combination program, Pfizer is managing monetary needs by paying Myovant up to USD 4.2 billion &#8211; a deal that is split into upfront payments, and sales and regulatory milestone payments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Audentes_Therapeutics_ASPIRO_Trial_Free_to_Proceed\"><\/span><strong>Audentes Therapeutics\u2019 ASPIRO Trial Free to Proceed&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After almost a tough year of holds, the U.S. The Food and Drug Administration (FDA) decided to lift the clinical ban from\u00a0 Audentes Therapeutics\u2019 ASPIRO trial, which was aimed at investigating its AT132 for the treatment of<a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-myotubular-myopathy-xlmtm-market?utm_source=blog&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\"> X-linked myotubular myopathy<\/a> (XLMTM), a rare neuromuscular disease.\u00a0<\/p>\n\n\n\n<p>The ASPIRO trial is a two-part, open-label ascending dose study, and is examining the safety and preliminary efficacy of AT132 in children with XLMTM younger than five years old. X-linked myotubular myopathy (XLMTM) is a rare genetic neuromuscular disorder and leads to muscle weakness, respiratory failure, and early death. Approximately 1 in 40,000 to 50,000 newborn males are diagnosed with the disease.<\/p>\n\n\n\n<p>The clinical hold was put after the death of three enrolled patients during the trial. However, as an early New year gift, the company can proceed with the trial keeping in mind a comprehensive view of past events.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Welcome_the_First_Generic_of_Drug_for_Severe_Hypoglycemia\"><\/span><strong>Welcome the First Generic of Drug for Severe Hypoglycemia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The U.S. Food and Drug Administration has given a green signal to the first generic of glucagon for injection USP, 1 mg\/vial packaged in an emergency kit, for the treatment of<a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-hypoglycemia-market?utm_source=blog&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\"> severe hypoglycemia<\/a>.\u00a0<\/p>\n\n\n\n<p>Severe hypoglycemia is a condition associated with very low blood glucose and is referred to as a diabetic emergency. It is a complication associated with diabetic patients who take insulin and certain anti-diabetic tablets. To overcome this, Glucagon, a hormone in the body, helps the liver to quickly increase blood sugar levels. Thus, the same idea is behind the injection which is a synthetic version of human glucagon. The most common side effects associated with glucagon for injection are nausea and vomiting, a temporary increase in heart rate, as well as redness and swelling of the injection site.<\/p>\n\n\n\n<p>The USFDA continually takes steps and initiatives to make high-quality generics available to people at affordable rates, and approval is another step in the direction.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teleflex_Acquires_Z-Medica\"><\/span><strong>Teleflex Acquires Z-Medica<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Teleflex Incorporated has finally completed the acquisition of Z-Medica, an industry-leading manufacturer of hemostatic products.<\/p>\n\n\n\n<p>Teleflex is a global manufacturer of medical technologies and equipment aiming to add value to the healthcare and pharmaceutical industry. The company boasts of its wide spectrum of portfolio ranging from solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology, and respiratory care. Acquisition of Z-Medica, is a Wallingford-based medical device company, will help bolster Teleflex\u2019s overall armamentarium.&nbsp;<\/p>\n\n\n\n<p>Teleflex a few months back had announced a definitive agreement to acquire Z-Medica. As per the terms and conditions of the agreement, Teleflex will pay an upfront cash payment of USD 500 million at closing along with an additional sum of USD 25 million on achieving certain commercial milestones. Teleflex also took home certain tax attributes that might prove fruitful to the company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A USD 4.2 Billion Myovant\/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women\u2019s health.\u00a0 Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. If approved, it will [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1130,460,498,16815,16814],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-11521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-generics","tag-pfizer","tag-prostate-cancer","tag-severe-hypoglycemia","tag-teleflex","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Myovant\/ Pfizer Deal; Generic for Severe Hypoglycemia; Teleflex\/Z-Medica<\/title>\n<meta name=\"description\" content=\"Myovant\/ Pfizer Deal; Audentes\u2019 ASPIRO Trial Free to Proceed; First Generic for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myovant\/ Pfizer Deal; Generic for Severe Hypoglycemia; Teleflex\/Z-Medica\" \/>\n<meta property=\"og:description\" content=\"Myovant\/ Pfizer Deal; Audentes\u2019 ASPIRO Trial Free to Proceed; First Generic for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-29T08:06:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Pharma Catch Up\" \/>\n<meta name=\"twitter:description\" content=\"A USD 4.2 Billion Myovant\/ Pfizer Deal; Audentes Therapeutics\u2019 ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Myovant\/ Pfizer Deal; Generic for Severe Hypoglycemia; Teleflex\/Z-Medica","description":"Myovant\/ Pfizer Deal; Audentes\u2019 ASPIRO Trial Free to Proceed; First Generic for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","og_locale":"en_US","og_type":"article","og_title":"Myovant\/ Pfizer Deal; Generic for Severe Hypoglycemia; Teleflex\/Z-Medica","og_description":"Myovant\/ Pfizer Deal; Audentes\u2019 ASPIRO Trial Free to Proceed; First Generic for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-12-29T08:06:52+00:00","article_modified_time":"2021-07-24T07:28:12+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_title":"Pharma Catch Up","twitter_description":"A USD 4.2 Billion Myovant\/ Pfizer Deal; Audentes Therapeutics\u2019 ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica","name":"Myovant\/ Pfizer Deal; Generic for Severe Hypoglycemia; Teleflex\/Z-Medica","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex.jpg","datePublished":"2020-12-29T08:06:52+00:00","dateModified":"2021-07-24T07:28:12+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Myovant\/ Pfizer Deal; Audentes\u2019 ASPIRO Trial Free to Proceed; First Generic for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-myovant-pfizer-audentes-teleflex-z-medica#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex.jpg","width":772,"height":482,"caption":"Myovant Pfizer Deal_Generic for Severe Hypoglycemia_Teleflex"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/29133346\/Myovant-Pfizer-Deal_Generic-for-Severe-Hypoglycemia_Teleflex-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">generics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Severe Hypoglycemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teleflex<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">generics<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Severe Hypoglycemia<\/span>","<span class=\"advgb-post-tax-term\">Teleflex<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 29, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 29, 2020 1:36 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Myovant Pfizer Deal_Generic for Severe Hypoglycemia_Teleflex","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11521"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11521\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11524"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11521"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11521"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}